Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DDO-2213 is a potent, orally active inhibitor of the WDR5-MLL1 interaction, demonstrating an IC50 of 29 nM and a Kd of 72.9 nM against WDR5. It selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity, and suppresses the proliferation of cells harboring MLL translocations, positioning it as a valuable tool for MLL fusion leukemia research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | DDO-2213 is a potent, orally active inhibitor of the WDR5-MLL1 interaction, demonstrating an IC50 of 29 nM and a Kd of 72.9 nM against WDR5. It selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity, and suppresses the proliferation of cells harboring MLL translocations, positioning it as a valuable tool for MLL fusion leukemia research [1]. |
Molecular Weight | 483.97 |
Formula | C24H27ClFN7O |
CAS No. | 2378768-36-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DDO-2213 2378768-36-4 inhibitor inhibit